Table 4.
Reported cases of LN after COVID-19 vaccination.
| Authors | Age | sex | PMH | Timeline of symptom onset | Type of Vaccine | Begin of symptoms | Serology profile | treatment | outcome |
|---|---|---|---|---|---|---|---|---|---|
| Zavala-Miranda et al. | 23 | F | N | 1 wk after 1st dose | Viral vector | eyelid edema foamy urine hair loss | ANA;anti-dsDNA; low C3 and C4 | mycophenolate mofetil; glucocorticoids; hydroxychloroquine; diuretics | R |
| Kim et al. | 60 | F | N | after 2nd dose | Viral vector | asthenic;did not eat well | ANA; anti-dsDNA; anti-Sm;low C3 and C4 | methylprednisolone; cyclophosphamide; Prednisolone; hydroxychloroquine | R |
| Nelson et al. | 14 | M | N | 2 days afte 3rd dose | mRNA | non-photosensitive facial rash | ANA;anti-dsDNA; anti-Sm;anti-RNP low C3 and C4 | Prednisone; mycophenolate mofetil; Losartan; hydroxychloroquine | R |
F, female; M, male; ANA,anti-nuclear antibody; anti-dsDNA,antibody recognizing double-strandded DNA; anti-RNP,anti-ribonuclear protein antibody;anti-Sm,anti-Smith antibody; N,none;NA, non-applicable; R, response.